Maelor's Volplex makes headway in Asian market:
This article was originally published in Clinica
UK company Maelor is building up its business throughout Asia with its plasma substitute product, Volplex, having extended its existing agreement with Chinese distributor, Helicon Group, to include South Korea. The Wrexham company made its debut in the Asian market in February this year after appointing Helicon as distributor of Volplex in China. According to Maelor, South Korea is the second largest pharmaceutical market in Asia after China, and it generated over $9bn in revenues in 2002.